TY - JOUR
TI - Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience
AU - Angelopoulou, M.K.
AU - Vassilakopoulos, T.P.
AU - Batsis, I.
AU - Sakellari, I.
AU - Gkirkas, K.
AU - Pappa, V.
AU - Giannoulia, P.
AU - Apostolidis, I.
AU - Apostolopoulos, C.
AU - Roussou, P.
AU - Panayiotidis, P.
AU - Dimou, M.
AU - Kyrtsonis, M.-C.
AU - Palassopoulou, M.
AU - Vassilopoulos, G.
AU - Moschogiannis, M.
AU - Kalpadakis, C.
AU - Margaritis, D.
AU - Spyridonidis, A.
AU - Michalis, E.
AU - Anargyrou, K.
AU - Repousis, P.
AU - Hatzimichael, E.
AU - Bousiou, Z.
AU - Poulakidas, E.
AU - Grentzelias, D.
AU - Harhalakis, N.
AU - Pangalis, G.A.
AU - Anagnostopoulos, A.
AU - Tsirigotis, P.
JO - Journal of Hematology & Oncology
PY - 2018
VL - 36
TODO - 1
SP - 174-181
PB - John Wiley and Sons Ltd
SN - 1756-8722
TODO - 10.1002/hon.2383
TODO - brentuximab vedotin;  antibody conjugate;  brentuximab vedotin, adult;  allogeneic stem cell transplantation;  Article;  autologous stem cell transplantation;  cancer chemotherapy;  cancer radiotherapy;  cancer recurrence;  cancer survival;  chemosensitivity;  disease control;  disease exacerbation;  female;  follow up;  Hodgkin disease;  human;  major clinical study;  male;  overall survival;  patient history of chemotherapy;  priority journal;  progression free survival;  retrospective study;  salvage therapy;  treatment failure;  clinical trial;  Hodgkin disease;  mortality;  multicenter study;  pathology;  prognosis;  survival analysis;  treatment outcome, Adult;  Female;  Hodgkin Disease;  Humans;  Immunoconjugates;  Male;  Prognosis;  Retrospective Studies;  Survival Analysis;  Treatment Outcome
TODO - This retrospective study aimed to describe the Hellenic experience on the use of brentuximab vedotin (BV) in relapsed/refractory (R/R) Hodgkin lymphoma (HL) given within its indication. From June 2011 to April 2015, ninety-five patients with R/R HL, who received BV in 20 centers from Greece, were analyzed. Their median age was 33 years, and 62% were males. Sixty-seven patients received BV after autologous stem cell transplantation failure, whereas 28 patients were treated with BV without a prior autologous stem cell transplantation, due to advanced age/comorbidities or chemorefractory disease. The median number of prior treatments was 4 and 44% of the patients were refractory to their most recent therapy. The median number of BV cycles was 8 (range, 2-16), and the median time to best response was the fourth cycle. Fifty-seven patients achieved an objective response: twenty-two (23%), a complete response (CR), and 35 patients (37%), a partial, for an overall response rate of 60%. Twelve patients (13%) had stable disease, and the remaining twenty-six (27%) had progressive disease as their best response. At a median follow-up of 11.5 months, median progression-free survival and overall survival were 8 and 26.5 months, respectively. Multivariate analysis showed that chemosensitivity to treatment administered before BV was associated with a significantly increased probability of achieving response to BV (P =.005). Bulky disease (P =.01) and response to BV (P <.001) were significant for progression-free survival, while refractoriness to most recent treatment (P =.04), bulky disease (P =.005), and B-symptoms (P =.001) were unfavorable factors for overall survival. Among the 22 CRs, 5 remain in CR with no further treatment after BV at a median follow-up of 13 months. In conclusion, our data indicate that BV is an effective treatment for R/R HL patients even outside clinical trials. Whether BV can cure a fraction of patients remains to be seen. © 2017 The Authors Hematological Oncology Published by John Wiley & Sons Ltd
ER -